5-HTP for Depression

Verdict: Weak, low-quality signal; safety concerns dominate

5-HTP shows a possible short-term benefit over placebo for depression, but the evidence rests almost entirely on small, dated, low-quality trials, and serious safety concerns mean it cannot be recommended over established treatments. It is not a substitute for therapy or prescription antidepressants.

B 🟡 B Preliminary Evidence Safety Review

🔬Why this grade7-layer evidence engine

The supportive data is thin. A Cochrane-derived 2002 review (PMID 12169147, PMID 11687048) found 5-HTP and L-tryptophan beat placebo (Peto OR 4.1, 95% CI 1.3-13.2), but only 2 of 108 located trials, totaling just 64 patients, met basic quality criteria, so the authors judged the evidence too weak to be conclusive. A 2020 meta-analysis (PMID 31504850) reported a high remission rate and a large effect (Hedges' g 1.11), yet its own authors flagged the pooled studies as methodologically weak with few placebo controls.

Regulators and clinics decline to endorse it. The US FDA states it cannot determine that 5-HTP can be safely used as a dietary supplement, and EFSA has rejected mood-related claims. The Mayo Clinic is cautious, noting some supplements may help some people but that more research on efficacy and side effects is needed, and that supplements cannot replace medical treatment.

Safety is the deciding factor. 5-HTP raises serotonin and can cause potentially dangerous serotonin syndrome when combined with SSRIs, SNRIs, or MAOIs, drugs many people with depression already take. Both Cochrane reviews also flag a possible link to the potentially fatal Eosinophilia-Myalgia Syndrome tied to contaminated tryptophan-class products. Given a weak evidence base and real harms, this earns a cautious preliminary grade with a safety review rather than a recommendation.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.60
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Safety Review
Confidence
74%
Broadly consistent
Evidence level
E1
Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.52
L2 PubMedPrimary literature
0.60
L3 MechanismPlausibility
0.75
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.597
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (3)L2 · primary research & systematic reviews

Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis (Cochrane-derived)
PMID: 12169147 2002 系統性回顧 n = 64
Finding: 5-HTP and L-tryptophan better than placebo at alleviating depression (Peto OR 4.1, 95% CI 1.3-13.2); only 2 of 108 located trials (64 patients) met quality criteria.
Academic Effect size: Peto OR 4.1 (95% CI 1.3-13.2)
View on PubMed
Tryptophan and 5-hydroxytryptophan for depression (Cochrane Database Systematic Review)
PMID: 11687048 2002 系統性回顧 n = 64
Finding: Evidence suggested benefit over placebo but of insufficient quality to be conclusive; possible association with potentially fatal Eosinophilia-Myalgia Syndrome noted.
Academic Effect size: Peto OR 4.1 (95% CI 1.3-13.2)
View on PubMed
Effects of 5-hydroxytryptophan on distinct types of depression: a systematic review and meta-analysis
PMID: 31504850 2020 統合分析
Finding: Pooled remission rate 0.65 (95% CI 0.55-0.78) and large effect on questionnaires (Hedges' g 1.11, 95% CI 0.53-1.69); but included studies relatively weak with few placebo groups.
🟠 Limited quality Academic Effect size: Hedges' g 1.11 (95% CI 0.53-1.69)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
FDA cannot determine that oral dosage forms of L-Tryptophan and related compounds such as L-5-hydroxytryptophan can be safely used as dietary supplements. source↗
L4d TW TFDA / 衛福部
Against
5-HTP在台灣並非合法的保健食品(食品)原料;色胺酸(L-tryptophan)則為合法之食品營養補充劑成分。 source↗
L5b Mayo Clinic
Cautious
For some people, some herbal and dietary supplements seem to help with depression. More studies are needed on how well they work and their side effects. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬3 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-depression-INT-5-htp-001 繁體中文版 →